Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
ACTOS - no renal reduction does not remove heart-failure risk
Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method
No renal-function dose bands specified for this summary.
Source revision
DailyMed updated 2025-03-28.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Official
ACTOS - no renal reduction does not remove heart-failure risk
NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method: No renal-function dose bands specified for this summary. Source date: DailyMed updated 2025-03-28. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Adult type 2 diabetes without heart failure: begin 15 or 30 mg orally daily, increasing by 15 mg as needed to at most 45 mg daily. For NYHA I-II heart failure the starting dose is 15 mg daily. Renal impairment does not require dose adjustment.
Fluid retention and heart-failure worsening remain major constraints; initiation is contraindicated in NYHA III-IV heart failure. A no-renal-adjustment statement is not permission to ignore edema, weight gain or dyspnea. Fixed combinations require review of every component.
RDM30-088-pioglitazone-1 · Source locator: ACTOS - no renal reduction does not remove heart-failure risk; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.